What’s New In Diffuse Large B-Cell Lymphoma

Target Audience

The educational design of this activity addresses the needs of hematologists/oncologists related to the treatment of B-cell non-Hodgkin lymphoma (NHL).

Program Overview

Diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin’s lymphoma (NHL), is the most common aggressive B-cell lymphoma, accounting for nearly 30% of all lymphomas.  Although chemoimmunotherapy has been the standard of care for first-line therapy, approximately 40% of cases will either relapse or be refractory and require additional treatment.  Fortunately, recent developments have led to tremendous advances in the treatment of both treatment-naïve and relapsed/refractory DLBCL. In this program, Dr. Sairah Ahmed reviews the latest and most pivotal clinical data on the management of DLBCL, as well as how best to apply these recent findings in clinical practice.

Educational Objectives

After completing this activity, the participant should be better able to:

• Describe the newer US Food and Drug Administration–approved therapies in various non-Hodgkin lymphoma subtypes
• Summarize the most recent clinical trial data on investigational therapies in non-Hodgkin lymphoma, emerging from recent hematology/oncology conferences
• Discuss approaches to implementation of new findings and therapeutic options in non-Hodgkin lymphoma therapies

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score at least 75% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Sairah Ahmed, MD: Consulting Fees: ADC Therapeutics SA, Kite Pharma/Gilead Sciences Inc.; Contracted Research: Chimagen Biosciences, Genmab A/S, Merck & Co., Inc., Nektar Therapeutics, Xencor, Inc.; Scientific Advisory Committee: Chimagen Biosciences; Data Safety Monitoring Board: Myeloid Therapeutics

John P. Winters III, MD: Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents (e.g., speakers’ bureaus): Bristol Myers Squibb

The planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.